Literature DB >> 11994932

Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version.

Grant L Iverson1, Grace A Hopp, Kimberley DeWolfe, Kevin Solomons.   

Abstract

BACKGROUND: The Neuropsychiatric Inventory-Nursing Home version (NPI-NH) is a modified version of the Neuropsychiatric Inventory (NPI). Accurate interpretation of change in the symptom ratings on the NPI-NH, as with any measure, is a concern for both clinicians and researchers. The purpose of this article is to present data for the interpretation of reliable change in the NPI-NH scores for acute geriatric neuropsychiatry patients.
METHOD: Fifty-two geriatric psychiatry inpatients were administered the NPI-NH twice, at a 72-hour interval. Standard errors of difference scores were used to calculate confidence intervals for each of the NPI-NH subscales and the total score.
RESULTS: Based on the calculations described above, estimates of reliable change on the individual subscales ranged from plus or minus 1.29 points on the Euphoria/Elation subscale to 5.13 points on the Anxiety subscale. Statistically meaningful change on the Agitation and the Apathy subscales was established at 4.0 and 4.3 points, respectively. A change in the total score of plus or minus 22 points is required to exceed the possible range of measurement error, at a 0.80 confidence interval (CI).
CONCLUSIONS: Overall, the results of this study indicate that the clinician evaluating elderly psychiatric inpatients should interpret a change in the total score of less than 22 points with caution, because it may be due to measurement error. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 11994932     DOI: 10.1002/gps.617

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  8 in total

Review 1.  Are the available apathy measures reliable and valid? A review of the psychometric evidence.

Authors:  Diana E Clarke; Jean Y Ko; Emily A Kuhl; Robert van Reekum; Rocio Salvador; Robert S Marin
Journal:  J Psychosom Res       Date:  2010-03-31       Impact factor: 3.006

2.  Light treatment for neuropsychiatric behaviors in Alzheimer's disease.

Authors:  Glenna A Dowling; Carla L Graf; Erin M Hubbard; Jay S Luxenberg
Journal:  West J Nurs Res       Date:  2007-06-27       Impact factor: 1.967

Review 3.  Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Authors:  Carole Parsons; Wei Yin Lim; Clement Loy; Bernadette McGuinness; Peter Passmore; Stephanie A Ward; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2021-02-03

4.  Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Authors:  Katherine A Treiber; Constantine G Lyketsos; Chris Corcoran; Martin Steinberg; Maria Norton; Robert C Green; Peter Rabins; David M Stein; Kathleen A Welsh-Bohmer; John C S Breitner; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2008-02-21       Impact factor: 3.878

5.  Quality of life of residents with dementia in long-term care settings in the Netherlands and Belgium: design of a longitudinal comparative study in traditional nursing homes and small-scale living facilities.

Authors:  Alida Hpm de Rooij; Katrien G Luijkx; Anja G Declercq; Jos Mga Schols
Journal:  BMC Geriatr       Date:  2011-05-03       Impact factor: 3.921

6.  Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.

Authors:  Myuri T Ruthirakuhan; Nathan Herrmann; Damien Gallagher; Ana C Andreazza; Alexander Kiss; Nicolaas Paul L G Verhoeff; Sandra E Black; Krista L Lanctôt
Journal:  Contemp Clin Trials Commun       Date:  2019-05-23

7.  Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial.

Authors:  Vered Hermush; Liora Ore; Noa Stern; Nisim Mizrahi; Malki Fried; Marina Krivoshey; Ella Staghon; Violeta E Lederman; Lihi Bar-Lev Schleider
Journal:  Front Med (Lausanne)       Date:  2022-09-06

8.  Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.

Authors:  Noll Campbell; Amir Ayub; Malaz A Boustani; Chris Fox; Martin Farlow; Ian Maidment; Robert Howards
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.